

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM585583

SUBMISSION TYPE:	RESUBMISSION		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
RESUBMIT DOCUMENT ID:	900556402		
SEQUENCE:	3		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Exela Sterile Medicines LLC		06/30/2020	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	Deerfield Private Design Fund IV, L.P.		
Street Address:	780 Third Avenue, 37th Floor		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10017		
Entity Type:	Limited Partnership: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	5055498	AKOVAZ	
Registration Number:	4433582	BLOXIVERZ	
Registration Number:	4704141	VAZCULEP	
CORRESPONDENCE DATA			
Fax Number:	6172890804		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2025361751		
Email:	doakes@brownrudnick.com		
Correspondent Name:	Peter J. Willsey, Brown Rudnick LLP		
Address Line 1:	601 Thirteenth Street NW Suite 600		
Address Line 4:	Washington, D.C. 20005		
ATTORNEY DOCKET NUMBER:	31378/14(TM SA DEERFIELD)		
NAME OF SUBMITTER:	Peter J. Willsey		
SIGNATURE:	/Peter J. Willsey/		
DATE SIGNED:	07/09/2020		

Total Attachments: 5

source=Deerfield - Exela - IP Security Agreement#page1.tif

source=Deerfield - Exela - IP Security Agreement#page2.tif

source=Deerfield - Exela - IP Security Agreement#page3.tif

source=Deerfield - Exela - IP Security Agreement#page4.tif

source=Deerfield - Exela - IP Security Agreement#page5.tif

**GRANT OF SECURITY INTEREST
IN PATENTS AND TRADEMARKS**

June 30, 2020

WHEREAS, EXELA STERILE MEDICINES LLC (the “Pledgor”) is the owner of the trademark applications and registrations listed on Schedule A attached hereto, (all such trademarks, registrations and applications, collectively, the “Trademarks”) and is the owner of the patents and patent applications listed on Schedule A attached hereto (all such patents, registrations and applications, collectively, the “Patents”); and

WHEREAS, as of the date hereof, the Pledgor has joined that certain Pledge and Security Agreement dated as of April 19, 2017 (as amended, modified, restated or supplemented from time to time, the “Security Agreement”), between Exela Holdings, Inc. and Deerfield Private Design Fund IV, L.P., as Collateral Agent (the “Collateral Agent”), with offices at 780 Third Avenue, 37th Floor, New York, New York 10017, pursuant to which the Pledgor has agreed with the Collateral Agent to execute this Grant;


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, as security for the payment and performance of the Secured Obligations (as defined in the Security Agreement), the Pledgor does hereby grant to the Collateral Agent a security interest in all of its right, title and interest in and to the Trademarks and the Patents, and the use thereof, together with all proceeds and products thereof and the goodwill of the businesses symbolized by the Trademarks. This Grant has been given in conjunction with the security interest granted to the Collateral Agent under the Security Agreement, and the provisions of this Grant are without prejudice to and in addition to the provisions of the Security Agreement, which are incorporated herein by this reference.

[Signature Page Follows]

IN WITNESS WHEREOF, the Pledgor has caused this Grant of Security Interest in Patents and Trademarks to be executed under seal by their duly authorized officers as of the date first above written.

EXELA STERILE MEDICINES LLC

By: Exela PharmSci, Inc., its sole member

By: 

Name: Phanesh B. Koneru

Title: President, Chief Financial Officer and Secretary

SCHEDULE A

TRADEMARKS AND TRADEMARK APPLICATIONS

<u>Owner</u>	<u>Trademark</u>	<u>Registration/ Application No.</u>	<u>Country</u>	<u>Registration/ Application Date</u>	<u>Status</u>
Exela Sterile Medicines LLC	AKOVAZ	5055498	United States	10/4/2016	Current
Exela Sterile Medicines LLC	BLOXIVERZ	4433582	United States	11/12/2013	Current
Exela Sterile Medicines LLC	VAZCULEP	4704141	United States	3/17/2015	Current

PATENTS AND PATENT APPLICATIONS

<u>Owner</u>	<u>Title</u>	<u>Application / Registration No.</u>	<u>Inventor</u>	<u>Country</u>	<u>Filing Date</u>	<u>Status</u>
Exela Sterile Medicines LLC	CYSTEINE COMPOSITION AND INJECTION	10,493,051	Angela Sutterer (US); Jill Simpson (US); Gauthier Pouliquen (FR); Alain Constancis (FR); Pierre Danner (FR)	United States	3/15/2019	Issued on Dec. 3, 2019
Exela Sterile Medicines LLC	CYSTEINE COMPOSITION AND INJECTION	10,543,186	Angela Sutterer (US); Jill Simpson (US); Gauthier Pouliquen (FR); Alain Constancis (FR); Pierre Danner (FR)	United States	4/2/2019	Issued on Jan. 28, 2020
Exela Sterile Medicines LLC	CYSTEINE COMPOSITION AND INJECTION	16/677,214	Angela Sutterer (US); Jill Simpson (US); Gauthier Pouliquen (FR); Alain Constancis (FR); Pierre Danner (FR)	United States	11/7/2019	Pending
Exela Sterile Medicines LLC	CYSTEINE COMPOSITION AND INJECTION	16/677,379	Angela Sutterer (US); Jill Simpson (US); Gauthier Pouliquen (FR); Alain Constancis (FR); Pierre Danner (FR)	United States	11/7/2019	Will issue as US Patent No. 10,702,490 on Jul. 7, 2020
Exela Sterile Medicines LLC	CYSTEINE COMPOSITION AND INJECTION	16/658,873	Angela Sutterer (US); Jill Simpson (US); Gauthier Pouliquen (FR); Alain Constancis (FR); Pierre Danner (FR)	United States	10/21/2019	Pending
Exela Sterile Medicines LLC	CYSTEINE COMPOSITION AND INJECTION	16/658,893	Angela Sutterer (US); Jill Simpson (US); Gauthier Pouliquen (FR); Alain Constancis (FR); Pierre Danner (FR)	United States	10/21/2019	Pending
Exela Sterile Medicines LLC	CYSTEINE COMPOSITION AND INJECTION	16/722,436	Angela Sutterer (US); Jill Simpson (US); Gauthier Pouliquen (FR); Alain Constancis (FR); Pierre Danner (FR)	United States	12/20/2019	Pending

New Drug Applications

<u>Owner</u>	<u>Title</u>	<u>Application / Registration No.</u>	<u>Inventor</u>	<u>Country</u>	<u>Filing Date</u>	<u>Status</u>
Exela Sterile Medicines LLC	Bloxiverz® (neostigmine hydrochloride injection)	N204078	N/A	United States	7/31/2012	Approved May 31, 2013
Exela Sterile Medicines LLC	Vazculep® (phenylephrine hydrochloride injection)	N204300	N/A	United States	6/28/2013	Approved June 27, 2014
Exela Sterile Medicines LLC	Akovaz® (ephedrine sulfate injection)	N208289	N/A	United States	6/30/2015	Approved April 29, 2016
Exela Sterile Medicines LLC	Nouress (cysteine hydrochloride injection)	N212535	N/A	United States	3/15/2019	Approved December 13, 2019